Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Immunic Inc IMUX

Healthcare Biotechnology

Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively,... see more

Add To Watchlist

Recent & Breaking News (NDAQ:IMUX)

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

PR Newswire 11 days ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire November 7, 2024

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

PR Newswire October 31, 2024

Immunic to Participate in Industry, Scientific and Investor Conferences in November

PR Newswire October 29, 2024

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

PR Newswire October 22, 2024

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

PR Newswire September 18, 2024

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

PR Newswire September 4, 2024

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

PR Newswire August 28, 2024

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire August 8, 2024

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

PR Newswire August 1, 2024

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

PR Newswire July 24, 2024

Immunic Appoints Jason Tardio as Chief Operating Officer and President

PR Newswire July 9, 2024

Immunic to Participate in Industry and Scientific Conferences in June

PR Newswire May 28, 2024

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire May 8, 2024

Immunic to Participate in Investor and Scientific Conferences in May

PR Newswire May 6, 2024

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

PR Newswire May 1, 2024

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

PR Newswire April 30, 2024

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

PR Newswire April 4, 2024

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

PR Newswire March 20, 2024

Immunic to Participate in Investor and Scientific Conferences in March

PR Newswire March 7, 2024